Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL

Phase III trial shows improved PFS in treatment of CLL using pirtobrutinib

Eli Lilly and Co. announced results from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.

December 13, 2024

Vol.50 No.46

Drugs & Targets

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Breyanzi CAR T-cell therapy in adults with R/R/ CLL or SLL

FDA has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor CAR T-cell therapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.

March 15, 2024

Vol.50 No.11

Clinical Roundup

Anti-cancer compound goes beyond current BTK inhibitors in CLL, other blood cancers

Researchers have identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia and related blood cancers.

February 02, 2024

Vol.50 No.05

Drugs & Targets

Elektrofi, Janssen Biotech form collaboration

Elektrofi Inc., a biopharmaceutical formulation technology has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech Inc., a Johnson & Johnson company.

January 05, 2024

Vol.50 No.01

Drugs & Targets

FDA approves Jaypirca in CLL/SLL indications

FDA approved Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor.

December 08, 2023

Vol.49 No.45

Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL

YOU MAY BE INTERESTED IN

Phase III trial shows improved PFS in treatment of CLL using pirtobrutinib

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

FDA approves Breyanzi CAR T-cell therapy in adults with R/R/ CLL or SLL

Anti-cancer compound goes beyond current BTK inhibitors in CLL, other blood cancers

Elektrofi, Janssen Biotech form collaboration

FDA approves Jaypirca in CLL/SLL indications

Renew today!

Subscriber content

Never miss an issue!

Login